Chinese Herbal Medicine Therapy Reduces the Risks of Overall and Anemia-Related Mortalities in Patients With Aplastic Anemia: A Nationwide Retrospective Study in Taiwan

Mu-Lin Chiu1,2†, Yu-Lung Hsu3†, Chao-Jung Chen2,4, Te-Mao Li1, Jian-Shiun Chiou5, Fuu-Jen Tsai1,2,3,6, Ting-Hsu Lin2, Chiu-Chu Liao2, Shao-Mei Huang2, Chen-Hsing Chou6, Wen-Miin Liang5* and Ying-Ju Lin1,2*

1School of Chinese Medicine, China Medical University, Taichung, Taiwan, 2Proteomics Core Laboratory, Department of Medical Research, Genetic Center, China Medical University Hospital, Taichung, Taiwan, 3China Medical University Children’s Hospital, China Medical University, Taichung, Taiwan, 4Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan, 5Department of Health Services Administration, China Medical University, Taichung, Taiwan, 6Department of Biotechnology and Bioinformatics, Asia University, Taichung, Taiwan

Aplastic Anemia (AA) is a rare but fatal hematologic disease that may occur at any age and especially higher in Asia. We investigated whether Chinese herbal medicine (CHM) is beneficial to AA patients as a complementary therapy using a nationwide population-based database in Taiwan between 2000–2016. Patient survival was estimated by Kaplan–Meier survival analyses and Cox proportional-hazard model. CHM-users presented lower risks of overall and anemia-related mortalities when compared to non-users. The risk of overall mortality for CHM-users in AA patients was 0.70-fold [adjusted hazard ratio (aHR): 0.70, 95% confidence interval (CI): 0.66-0.74, p < 0.001). The risk of anemia-related mortality was lower in CHM-users when compared to non-users (aHR: 0.46, 95% CI: 0.32-0.67, p < 0.001). The association rule analysis revealed that CHM pairs were Ban-Zhi-Lian (BZL; Scutellaria barbata D. Don) → Bai-Hua-She-She-Cao (BHSSC; Oldenlandia diffusa (Willd.) Roxb.), followed by Dang-Gui (DG; Angelica sinensis (Oliv.) Diels) → Huang-Qi (HQi; Astragalus membranaceus (Fisch.) Bunge), and Xian-He-Cao (XHC; Agrimonia pilosa f. borealis (Kitag.) Chu) → Gui-Pi-Tang (GPT). Network analysis showed that BZL, BHSSC, DG, HQi, XHC, GPT, and Dan-Shen (DanS; Salvia miltiorrhiza var. charbonnelli (H.Lév.) C.Y.Wu) were commonly used CHMs for AA patients. Therefore, further studies for these commonly prescribed herbs are needed in functional investigations in hematopoiesis-stimulating effect and large-scale randomized controlled trials (RCT) in bone marrow failure related diseases.

Keywords: aplastic anemia, overall mortality, anemia-related mortality, Chinese herbal medicine, network analysis
**INTRODUCTION**

Aplastic anemia (AA) is a rare but fatal hematologic and auto-immune disease (Clucas et al., 2019; Furlong and Carter, 2020), which mainly occurs in individuals from Asian countries (Vaht et al., 2017; Chiu et al., 2017; Li et al., 2019). The incidence of AA is below 2.5 cases/million/year in Europe and America; however, higher incidence of AA is observed with 7.4 cases/million/year in China, 4.8 cases/million/year in Malaysia, and 5.67 cases/million/year in Taiwan (Vaht et al., 2017; Li et al., 2019). AA may occur at any age and is characterized with bone marrow failure syndrome and pancytopenia in peripheral blood (Peslak et al., 2017). It is known that immune-mediated destruction of hematopoiesis is the major pathogenesis of AA (Medinger et al., 2018). In AA patients, dysregulated and self-reacted cytotoxic T cells secrete pro-inflammatory cytokines, target hematopoietic stem and progenitor cells, induce cell death, and result in hematopoietic failure (Socie et al., 1993; Nakao et al., 2005; Zeng and Katsanis, 2015; Medinger et al., 2018; Ding et al., 2019; Liu et al., 2020).

The major AA treatment includes anti-thymocyte globulin (ATG)-based immunosuppressive therapy (IST) and hematopoietic stem cell transplantation (HSCT) (Speck et al., 1981; Bacigalupo et al., 2000). Other treatment includes glucocorticoid usage, blood transfusion therapy, hematopoietic growth factor therapy, chemotherapy, iron chelation therapy, and androgen therapy etc (Gale et al., 1981; Gurion et al., 2009). With these treatments in patients with AA, the 5-years survival rate approaches 60–80% (Vaht et al., 2017; Li et al., 2019). However, IST belongs to lymphocytotoxic agents, and some of these agents have cause complications, such as anaphylaxis fever, chest pain, diarrhea, infections, and subsequent malignant conditions (Socie et al., 1993; Passweg and Aljurf, 2013; Fu et al., 2017; van der Hem et al., 2017). For HSCT, it is very hard to find a matched donor, making this treatment less favorable when compared with IST (Zhu et al., 2016). Therefore, modulating anti-inflammatory, anti-complement, anti-cancer, anti-oxidant, anti-microbial, immune-modulating as well as hematopoiesis-stimulating based therapeutic strategies may be beneficial for AA patients (Socie et al., 1993; Nakao et al., 2005; Fu et al., 2017; van der Hem et al., 2017; Chatterjee and Law, 2018; Ding et al., 2019; Liu et al., 2020).

There is a need for seeking alternative therapies for the possible combination with the current conventional therapies. Studies in Chinese herbal medicines (CHMs) and related natural compounds show as effective, safe, less toxic and few side-effects in bone marrow failure related diseases (Gao and Chong, 2012; Zhu N. et al., 2018; Sun et al., 2018; Liu WB. et al., 2019). Furthermore, In Taiwan, CHMs have been widely used in many diseases (Lin et al., 2015; Li et al., 2018; Lee et al., 2019; Tsai et al., 2019; Wang CY. et al., 2020; Wu et al., 2020; Ho et al., 2021). Taiwanese AA patients may also choose CHM as their integrative, alternative, and complementary therapy to reduce complications from conventional therapies and to improve the overall survival rate.

In this study, we therefore used a nationwide population-based database in Taiwan to perform a retrospective cohort study and evaluate the CHM effect on overall and anemia-related mortalities for patients with AA. The CHM prescription pattern was also investigated from those with lower risks of overall and anemia-related mortalities.

**MATERIALS AND METHODS**

**Database Source**
We used a longitudinal medical claims data, National Health Insurance Research Database (NHIRD) of Taiwan, to investigate the risks of overall and anemia-related mortalities between CHM and non-CHM users in AA patients during the period between January 1, 2000 and December 31, 2016. In total, 28,867,331 beneficiaries were included in this database. The diseases were identified by the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes. The informed consent was not demanded because all of the personal data were de-identified. The Institutional Review Board (IRB) issued the ethical approval to this study (CMUH107-REC3-074 (CR1)) at China Medical University Hospital.

**Study Subjects**
In this study, there were 42,195 patients with aplastic anemia (AA) (ICD-9-CM-code: 284) identified during the period between January 1, 2003 and December 31, 2013 (Figure 1). We excluded 25,146 patients with AA. These excluded AA patients were with incorrect data (N = 7), death before the index date (N = 8), splenectomy during the study period (N = 566), bone marrow transplantation during the study period (N = 943), and cumulative CHM days <14 days within 1 year after AA diagnosis (N = 23,622). During the follow-up period, there were 5,346 CHM-users and 11,703 non-CHM users among AA patients. To eliminate potential bias caused by confounders, the CHM users and non-users were matched by age, gender, Charlson comorbidity index (CCI) score, immunosuppressive therapy, glucocorticoid usage, hematopoietic growth factor therapy, androgen therapy, chemotherapy, iron chelation therapy, and blood transfusion therapy using the propensity score matching method at 1:1 ratio. After matching, 3,709 CHM-user and 3,709 non-CHM-user matched pairs were identified (Figure 1 and Table 1). The date with a completed accumulation of 14 CHM days within 1 year after AA diagnosis was designated as the index date (Figure 2). Those who continued to use CHMs after the index date were designated as the CHM-users. The study endpoint was the end of 2016, death, or withdrawal from the NHIRD.

**Chinese Herbal Medicine**
Single herb and herbal formula are two types of CHM products used in AA patients. A single herb was a part of a plant, including flowers, fruits, seeds, stems, roots, and leaves. The organs of animals, insects, or minerals also can be used as the single herb. The herbal formula contained at least two single herbs. In our study, the CHM prescriptions (Table 2 and Supplementary Table S1) for AA patients were prescribed by licensed doctors.
of traditional Chinese medicine in Taiwan. These Chinese herbal medicine were manufactured by Taiwan’s pharmaceutical companies with the certificate of Good Manufacturing Practice (GMP) (Li et al., 2018; Cheng et al., 2019; Tsai et al., 2019).

Association Rule

We used association rule to investigate the prescription profile of CHM (Yang et al., 2013). SAS software (version 9.4; SAS Institute, Cary, NC, United States) was used to implement the association rule as previous studies for CHM pairs (Wang CY. et al., 2020; Wu et al., 2020; Ho et al., 2021). The lift value, support value (X) (%), and confidence value (CHM_X→CHM_Y; %) presented the association strength between CHM pairs (CHM products X and Y) as previous studies (Table 3).

Network Analysis

Cytoscape was used to accomplish network analysis for CHM clusters as previous studies described (Yang et al., 2013; Wang CY. et al., 2020; Wu et al., 2020; Ho et al., 2021). A red circle indicated the herbal formula, and a green circle indicated a single herb. The prescription frequency of CHM was presented by the circle size. The support value between CHM pairs was signified by the line size. The lift value between CHM pairs was displayed by line color. The strength of stronger connection between CHM pairs was shown by the thicker and darker connection line (Figure 3).

Statistical Analysis

Categorical data was shown as numbers (percentages), including age, gender, Charlson comorbidity number, immunosuppressive therapy (IST), glucocorticoid usage, hematopoietic growth factor therapy, androgen therapy, chemotherapy, iron chelation therapy, and blood transfusion therapy. The differences between CHM-users and non-users were evaluated by Chi-squared test (Table 1). Continuous data was shown as mean ± standard deviation, such as CCI score. The differences between CHM and non-CHM users were evaluated by Student’s t test (Table 1). The risks of overall and anemia-related mortalities in AA patients was estimated using the crude and adjusted Cox proportional hazard models (Table 4). We adjusted the confounding factors including age, gender, comorbidities, glucocorticoid usage, and the use of immunosuppressive therapy, hematopoietic growth factor therapy, androgen therapy, chemotherapy, iron chelation therapy, and blood transfusion therapy (Table 4). The cumulative incidence of overall mortality between CHM and non-CHM users was assessed by Kaplan–Meier curves and log-rank tests (Supplementary Figure S1). p-values < 0.05 were considered statistically significant. SAS software (version 9.4; SAS Institute) was utilized to perform all of the analyses.

RESULTS

Demographic Characteristics

The demographic characteristics of patients with aplastic anemia (AA) in Taiwan were shown in Table 1. During the study period, there were 5,346 CHM users and 11,703 non-CHM users among AA patients in this study. Age, gender, comorbidities, glucocorticoid usage, and the use of hematopoietic growth factor therapy, chemotherapy, androgen therapy, iron chelation therapy, and blood transfusion therapy were significantly different between CHM and non-CHM users (p < 0.05; Table 1). The propensity score was performed to decrease potential confounders. After matching, there were 3,709 CHM-users and 3,709 non-CHM users. There were no significant differences in demographic characteristics between these two groups after matching (p > 0.05; Table 1).

Overall Mortality

The crude hazard ratios (HR) and adjusted hazard ratios (aHR) showed that the risk of overall mortality in AA patients significantly increased with age (Table 4). AA patients aged ≥65 years had 6.21 times higher overall mortality risk than those under 18 years of age even after adjusting for confounding factors [aHR: 6.21, 95% confidence interval (CI):
5.02–7.68, p < 0.001; Table 4). Females presented a significantly lower overall mortality risk than males (HR: 0.77, 95% CI: 0.72–0.82, p < 0.001; aHR: 0.76, 95% CI: 0.71–0.81, p < 0.001; Table 4). The risk of overall mortality was significantly lower in CHM-users when compared to non-CHM users (aHR: 0.70, 95% CI: 0.66–0.74, p < 0.001; Table 4). The difference in the cumulative incidence of overall mortality between CHM and non-CHM users was displayed by Kaplan–Meier survival plots (Supplementary
with the use of Dan-Shen (DanS; *Salvia miltiorrhiza var. charbonnelli* (H.Lév.) C.Y.Wu) had a lower risk of overall mortality when compared to non-DanS users (aHR: 0.58, 95% CI: 0.53-0.63, \(p < 0.001\); Table 5). Patients with the use of Huang-Qi [HQi; *Astragalus membranaceus* (Fisch.) Bunge], Bai-Hua-She-She-Cao [BHSSC; *Oldenlandia diffusa* (Willd.) Roxb.], Ban-Zhi-Lian (BZL; *Scutellaria barbata* D. Don), Xian-He-Cao (XHC; *Agrimonia pilosa f. borealis* (Kitag.) Chu), and Dang-Gui (DG; *Angelica sinensis* (Oliv.) Diels) were found to have a lower risk of overall mortality when compared to the users of non-HQi (aHR: 0.57, 95% CI: 0.52-0.61, \(p < 0.001\)), non-BHSSC (aHR: 0.79, 95% CI: 0.71-0.88, \(p < 0.001\)), non-BZL (aHR: 0.79, 95% CI: 0.70-0.88, \(p < 0.001\)), non-XHC (aHR: 0.65, 95% CI: 0.58-0.73, \(p < 0.001\)), and non-DG (aHR: 0.50, 95% CI: 0.45-0.56, \(p < 0.001\)), respectively (Table 5). For anemia-related mortality, we observed that patients with CHM use had the statistical significance of a lower risk of anemia-related mortality (aHR: 0.46, 95% CI: 0.32–0.67, \(p < 0.001\); Table 5).

However, there were no significant protective effect against anemia-related mortality for these commonly prescribed herbs after adjusting for potential confounding factors (\(p > 0.05\); Table 5).

There were 3,709 patients who had 121,770 prescriptions provided by the doctors of traditional Chinese medicine in Taiwan (Table 3). The most frequently prescribed CHM pairs for AA patients in Taiwan was analyzed by using the association rule (Table 3). Higher levels of lift, confidence, and support values indicated stronger associations between CHM pairs. As shown, the most frequently prescribed CHM pairs were Ban-Zhi-Lian (BZL; *Scutellaria barbata* D. Don)\(\rightarrow\)Bai-Hua-She-She-Cao (BHSSC; *Oldenlandia diffusa* (Willd.) Roxb.) (first co-prescription frequency: 3,661, support: 0.30%, confidence: 60.59%, lift: 10.90), followed by Dang-Gui (DG; *Angelica sinensis* (Oliv.) Diels)\(\rightarrow\)Huang-Qi [HQi; *Astragalus membranaceus* (Fisch.) Bunge] (second co-prescription frequency: 3,661, support: 3.01%, confidence: 60.59%, lift: 10.90) and Xian-He-Cao (XHC; *Agrimonia pilosa f. borealis* (Kitag.) Chu)\(\rightarrow\)Gui-Pi-Tang (GPT) (third co-prescription frequency: 1,345, support: 1.10%, confidence: 33.33%, lift: 4.73) (Table 3).

The prescription network of CHM for AA patients in Taiwan was presented by network analysis (Figure 3). Our results revealed that there was one main CHM cluster. In this one main cluster, Gui-Pi-Tang (GPT), Dan-Shen [DanS; *Salvia miltiorrhiza var. charbonnelli* (H.Lév.) C.Y.Wu], Huang-Qi (HQi; *Astragalus membranaceus* (Fisch.) Bunge), Dang-Gui (DG; *Angelica sinensis* (Oliv.) Diels), Bai-Hua-She-She-Cao [BHSSC; *Oldenlandia diffusa* (Willd.) Roxb.], Ban-Zhi-Lian (BZL; *Scutellaria barbata* D. Don), Xian-He-Cao (XHC; *Agrimonia pilosa f. borealis* (Kitag.) Chu), and Dang-Gui (DG; *Angelica sinensis* (Oliv.) Diels) were important CHMs for AA patients. Among them, the most frequently prescribed herbal formula and single herb were GPT and DanS, respectively (Table 2 and Figure 3). The strongest connection strength was between BHSSC and BZL, and the second one was between HQi and DG (Table 3 and Figure 3).
TABLE 2 | Composition of the most commonly used herbal formulas and single herbs for patients with aplastic anemia in Taiwan.

| Formulas                  | Chinese name (Pin-yin name) | Number of herbs | Composition (pin-yin name (Latin name; botanical plant name)) | Frequency of prescriptions | Person-year | Percentage of usage person | Avg. drug dose per day (g) | Average duration for prescription (days) |
|---------------------------|----------------------------|-----------------|---------------------------------------------------------------|---------------------------|-------------|-----------------------------|--------------------------|----------------------------------------|
| Total                     | —                          | —               | —                                                             | 121770                    | 17492.00    | 100.00                      | 13.40                    | 8.84                                   |
| Herbal formula (Pin-yin name) | —                          | —               | —                                                             | 116887                    | 17438.20    | 99.27                       | 9.53                     | 8.78                                   |
| Gui-Pi-Tang (GPT)         | 銀柴湯                      | 12              | Ren-Shen (Radix Ginseng; Panax ginseng var. repens (Maxim.) Makino), Huang-Qi (Radix Astragali; Astragalus membranaceus (Fisch.) Bunge), Bai-Zhu (Rhizoma Atractylodis Macrocephalae; Atractyls macrocephala (Koidz.) Hand.-Mazz.), Fu-Ling (Poria; Wolfiporia cocos (F.A. Wolf) Ryvarden & Gilb), Suan-Zao-Ren (Serren Zizyphi Spinosa; Ziziphus jujuba f. lageniformis (Nakai) Kitag.), Long-Yan-Rou (Anulus Longan; Dimocarpus longan var. obtusus (Pierre) Leenh.), Mu-Xiang (Radix Aucklandiae; Himataila abormmis (Lipsch.) Raab-Straube), Gan-Cao (Radix Glycyrrhiza; Glycyrrhiza glabra var. glandulifera (Waldst. and Kit.) Boiss.), Dang-Gui (Radix Angelicae Sinensis; Angelica sinensis (Oliv.) Diets), Yuan-Zhi (Radix Polygala; Polygala sibica var. tenuifolia (Willd.) Backer & Moore), Sheng-Jiang (Rhizoma Zingiberis Recens; Zingiber officinale f. rubens (Makino) M.Hiroe), Da-Zao (Fructus Jujube; Ziziphus jujuba f. lageniformis (Nakai) Kitag.) | 8,588                     | 6,442.00    | 31.52                       | 4.78                     | 10.87                                   |
| Single herbs (Pin-yin name) | —                          | —               | —                                                             | 102198                    | 17018.60    | 96.12                       | 5.01                     | 9.07                                   |
| Dan-Shen (DanS)           | 丹参                        | 1               | Dan-Shen (Radix Salviae Mittohmiae; Salvia miltiorrhiza var. charbonnelli (H.Lév.) C.Y.Wu) | 9,867                     | 7,646.20    | 36.42                       | 1.38                     | 10.54                                   |
| Huang-Qi (HQi)            | 黃耆                        | 1               | Huang-Qi (Radix Astragali; Astragalus membranaceus (Fisch.) Bunge) | 9,058                     | 7,262.00    | 34.65                       | 1.52                     | 10.45                                   |
| Bai-Hua-She-Cao (BHSSC)   | 白花蛇                      | 1               | Bai-Hua-She-Cao (Herba Hedycotis Diffusae; Oldenlandia diffusa (Willd.) Roxb.) | 6,767                     | 2,685.70    | 15.83                       | 1.51                     | 12.76                                   |
| Ban-Zhi-Lian (BZL)        | 半枝蓮                      | 1               | Ban-Zhi-Lian (Herba Scutellariae Barbatae; Scutellariae barbatae D. Don) | 6,042                     | 2,171.00    | 11.86                       | 2.24                     | 12.11                                   |
| Xian-He-Cao (XHC)         | 仙鶴草                      | 1               | Xian-He-Cao (Herba Agrimoniae; Agrimoniae pilosa f. borealis (Kitag.) Chu) | 4,038                     | 2,941.40    | 14.37                       | 1.32                     | 11.95                                   |
| Dang-Gui (DG)             | 當歸                        | 1               | Dang-Gui (Radix Angelicae Sinensis; Angelica sinensis (Oliv.) Diets) | 3,712                     | 4,445.40    | 19.52                       | 1.10                     | 10.07                                   |

*Sorted by frequency of prescriptions.

Information are obtained from the websites (http://www.americandragon.com/index.htm; http://old.tcmwiki.com/; http://www.shen-nong.com/eng/front/index.html; http://www.ipni.org/; http://www.theplantlist.org; http://www.worldfloralonline.org/).

DISCUSSION

Chinese herbal medicines (CHMs) exhibit effective, safe, less toxic and few side-effects in bone marrow failure related diseases (Gao and Chong, 2012; Zhu N. et al., 2018; Sun et al., 2018; Liu WB. et al., 2019). Long-term CHM effect on aplastic anemia (AA) patients remains to be elucidated. In this study, we conducted a population-based retrospective cohort study to investigate the CHM effect on overall and anemia-related mortalities for these patients using a nationwide population-based database in Taiwan. We found that AA patients who used CHM had significantly lower risks of overall and anemia-related mortalities. Furthermore, we found that one CHM main cluster were important for these AA patient. This one main CHM cluster is composed by seven CHMs- Ban-Zhi-Lian (BZL; Scutellaria barbata D. Don), Bai-Hua-She-She-Cao (BHSSC; Oldenlandia diffusa (Willd.) Roxb.), Dan-Shen (DanS; Salvia miltiorrhiza var. charbonnelli (H.Lév.) C.Y.Wu), Huang-Qi (HQi; Astragalus membranaceus (Fisch.) Bunge), Xian-He-Cao (XHC; Agrimonia pilosa f. borealis (Kitag.) Chu),
Dang-Gui [DG; Angelica sinensis (Oliv.) Diels], and Gui-Pi-Tang (GPT). These results may suggest that CHMs exhibit the protective effect against overall and anemia-related mortalities in AA patients and may provide the utility of clinical CHM as an alternative therapy for the possible combination with the current conventional therapies for these patients.

We found that AA patients with over 65 years old had higher overall and anemia-related mortalities in Taiwan. For overall mortality, AA patients over 65 years old had a higher risk of 6.21-fold than those aged younger than 18 years old. This is consistent with previous studies (Vaht et al., 2017; Contejean et al., 2019). Among AA patients, especially for those who older than 60 years of age. We also found that among AA patients, patients who used CHMs had lower risks of overall and anemia-related mortalities even after adjusting for age, gender, comorbidities, and usages of immunosuppressive therapy, glucocorticoid usage, hematopoietic growth factor therapy, androgen therapy, chemotherapy, iron chelation therapy, and blood transfusion therapy. CHMs may show the protective effect against bone marrow failure related diseases (Gao and Chong, 2012; Kuang et al., 2016; Sun et al., 2018; Jiang et al., 2021). Ginseng extract and its active component-panaxadiol saponins promote the proliferation and differentiation of hematopoietic progenitor cells and then regulate the immune function (Gao and Chong, 2012; Kuang et al., 2016; Sun et al., 2018; Jiang et al., 2021).

For AA patients in Taiwan, we found one main CHM cluster composed by seven CHMs- BZL (Scutellaria barbata D. Don), BHSSC [Oldenlandia diffusa (Willd.) Roxb.], DanS [Salvia miltiorrhiza var. charbonnelii (H.Lév.) C.Y.Wu], HQi [Astragalus membranaceus (Fisch.) Bunge], XHC [Agrimonia pilosa f. borealis (Kitag.) Chul], DG [Angelica sinensis (Oliv.) Diels], and GPT. The strongest connection strength was between BZL and BHSSC. Ban-Zhi-Lian (BZL), also named Scutellaria barbata D. Don, is a flowering plant of family Lamiaceae. Polysaccharides from BZL exhibit anti-complement activity and have been recommended to treat complement-associated diseases (Wu and Chen, 2009; Wu et al., 2009). Bai Hua She She Cao (BHSSC), also known as Oldenlandia diffusa (Willd.) Roxb., belongs to family Rubiaceae (Liang et al., 2008). BHSSC promotes blood circulation, clears heat away, removes dampness, and eliminates toxins. BHSSC also has immunomodulating, anti-inflammatory, and anti-cancer effects (Shan et al., 2001; Gupta et al., 2004; Zhu et al., 2018a). For single herbs, DanS [Salvia miltiorrhiza var. charbonnelii (H.Lév.) C.Y.Wu] was the most prescribed single herb in our study. DanS is the dry root and rhizome of Salvia miltiorrhiza var. charbonnelii (H.Lév.) C.Y.Wu of family Lamiaceae. Tanshinones are

### Table 2: Most commonly used pairs of CHM products for patients with aplastic anemia in Taiwan.

| CHM products (LHS, X) | Chinese name | Frequency of prescriptions of X product | CHM products (RHS, Y) | Chinese name | Frequency of prescriptions of Y product | Frequency of prescriptions of X and Y product | Support (X) (%) | Confidence (X → Y) (%) | Lift |
|----------------------|-------------|----------------------------------------|----------------------|-------------|----------------------------------------|-----------------------------------------------|--------------|-----------------------|------|
| Ban-Zhi-Lian (BZL; Scutellaria barbata D.Don) | 半枝蓮 | 6,042 | Ban-Zhi-Lian (BZL; Scutellaria barbata D.Don) | 半枝蓮 | 6,767 | 3,661 | 3.01 | 60.59 | 10.90 |
| Dang-Gui (DG; Angelica sinensis (Oliv.) Diels) | 当歸 | 3,712 | Huang-Qi (HQi; Astragalus membranaceus (Fisch.) Bunge) | 黃耆 | 9,058 | 1,778 | 1.46 | 47.90 | 6.44 |
| Xian-He-Cao (XHC; Agrimonia pilosa f. borealis (Kitag.) Chul) | 西銀草 | 4,036 | Gu-Pi-Tang (GPT) | 脾湯 | 8,588 | 1,345 | 1.10 | 33.33 | 4.73 |
| Huang-Qi (HQi; Astragalus membranaceus (Fisch.) Bunge) | 黃耆 | 9,058 | Dan-Sen (DanS; Salvia miltiorrhiza var. charbonnelii (H.Lév.) C.Y.Wu) | 丹參 | 9,867 | 1,241 | 1.02 | 13.70 | 1.69 |
| Bai-Hua-She-She-Cao (BHSSC; Scutellaria barbata D.Don) | 白花蛇舌草 | 6,767 | Dan-Sen (DanS; Salvia miltiorrhiza var. charbonnelii (H.Lév.) C.Y.Wu) | 丹參 | 9,867 | 1,207 | 0.99 | 17.84 | 2.20 |

CHM, Chinese herbal medicine; LHS, left-hand-side; RHS, right-hand-side. Total prescriptions = 121,770.
Support (X) (%) = Frequency of prescriptions of X and Y products/total prescriptions x 100.
Confidence (X → Y) (%) = Frequency of prescriptions of X and Y products/Frequency of prescriptions of X product x 100.
Lift = Lift = Π[ifi=1](Y/SY) / Π[ifi=1](Y/SY).
P (Y) (%) = Frequency of prescriptions of Y product/total prescriptions x 100.

Pin-yin and botanical plant names for Chinese herbs were obtained from the websites [http://www.americanfork.com/index.htm; http://old.tcmwiki.com; http://www.shen-nong.com/eng/front/index.html; http://www.ipni.org; http://www.theplantlist.org; http://www.worldfloraonline.org].
isolated from DanS, regulate metabolic function, and provide vasodilation, neuroprotection, anti-oxidation, anti-inflammation, anti-tumor, and phytoestrogenic activities (Wang X. et al., 2020). Also from DanS, salvianolic acid B shows anti-oxidant, anti-inflammatory, and anti-cancer activities (Shi et al., 2019).

The second most commonly used CHM pairs were HQi and DG. The combination of DG and HQi is widely used to treat iron-deficiency anemia, because it could increase iron through the biosynthesis of ferritin and improve the level of hemoglobin (Huang et al., 2016). Furthermore, DG and HQi recover the function of hematopoietic stem cells, balance T lymphocytes, inhibit the apoptosis of bone marrow cells induced by immune attack, and restore the balance of the T cell immune response (Liu J. et al., 2019). HQi, also known as Astragalus membranaceus (Fisch.) Bunge, is a flowering plant in the family Fabaceae. HQi is effective to treat chronic aplastic anemia by promoting the recovery of hematopoietic function through improving T-lymphocyte subsets and reducing the release of negative regulatory factors such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-2 (IL-2) (Wang et al., 2007). Animal experiment shows that HQi increases serum megakaryocyte colony-stimulating activity (Meg-CSA) of anemic mice and accelerates the recovery of megakaryocyte hematopoiesis (Zhu and Zhu, 2001). Meta-analysis also reports that HQi significantly enhances the efficacy of androgens for aplastic anemia without severe side effects (Zhu et al., 2015). Dang-Gui (DG), also known as Angelica sinensis (Oliv.) Diels, belongs to the family Apiaceae. Angelica sinensis polysaccharide (ASP) from DG, is effective for the treatment of aplastic anemia (Chen et al., 2020). ASP could prevent mitochondrial apoptosis to restore the function of hematopoietic stem cells by suppressing abnormal T-cell immunity. Moreover, ASP inhibits NF-κB p65 activation via the IκB kinases- (IKKs-) IκBα pathway,
TABLE 5 | Cox proportional hazard models for risk of overall and anemia-related mortalities in patients with aplastic anemia (stratified by herb use).

| CHM use | Crude HR | 95% CI | p-value | Adjusted aHR | 95% CI | p-value | Crude HR | 95% CI | p-value | Adjusted aHR | 95% CI | p-value |
|---------|----------|--------|---------|------------|--------|---------|----------|--------|--------|------------|--------|---------|
| No      | 1.00     | NA     | NA      | 1.00       | NA     | NA      | 1.00     | NA     | NA     | 1.00       | NA     | NA      |
| Yes     | 0.74     | (0.71–0.78) | <0.001 | 0.70       | (0.66–0.74) | <0.001 | 0.49     | (0.34–0.70) | <0.001 | 0.46       | (0.32–0.67) | <0.001 |
| Gui-Pi-Tang (GPT) | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA |
| No      | 1.00     | NA     | NA      | 1.00       | NA     | NA      | 1.00     | NA     | NA     | 1.00       | NA     | NA      |
| Yes     | 0.62     | (0.57–0.68) | <0.001 | 0.63       | (0.58–0.69) | <0.001 | 1.14     | (0.73–1.78) | 0.555 | 0.82       | (0.51–1.31) | 0.395 |
| Dan-Shen (Dans; Salvia miltiorrhiza var. charbonnelli (H.Lév.) C.Y.Wu) | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA |
| No      | 1.00     | NA     | NA      | 1.00       | NA     | NA      | 1.00     | NA     | NA     | 1.00       | NA     | NA      |
| Yes     | 0.57     | (0.53–0.62) | <0.001 | 0.58       | (0.53–0.63) | <0.001 | 0.76     | (0.47–1.24) | 0.276 | 0.81       | (0.5–1.32) | 0.402 |
| Huang-Qi (HQi; Astragalus membranaceus (Fisch.) Bunge) | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA |
| No      | 1.00     | NA     | NA      | 1.00       | NA     | NA      | 1.00     | NA     | NA     | 1.00       | NA     | NA      |
| Yes     | 0.57     | (0.52–0.61) | <0.001 | 0.57       | (0.52–0.61) | <0.001 | 0.76     | (0.47–1.25) | 0.278 | 0.70       | (0.42–1.16) | 0.163 |
| Bai-Hua-She-She-Cao (BHSSC; Oldenlandia diffusa (Willd.) Roxb.) | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA |
| No      | 1.00     | NA     | NA      | 1.00       | NA     | NA      | 1.00     | NA     | NA     | 1.00       | NA     | NA      |
| Yes     | 0.97     | (0.87–1.08) | 0.558 | 0.79       | (0.71–0.88) | <0.001 | 0.37     | (0.14–0.98) | 0.046 | 0.42       | (0.16–1.16) | 0.094 |
| Ban-Zhi-Lian (BZL; Scutellaria barbata D.Don) | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA |
| No      | 1.00     | NA     | NA      | 1.00       | NA     | NA      | 1.00     | NA     | NA     | 1.00       | NA     | NA      |
| Yes     | 0.97     | (0.87–1.09) | 0.608 | 0.79       | (0.70–0.88) | <0.001 | 0.24     | (0.06–0.98) | 0.046 | 0.36       | (0.09–1.49) | 0.160 |
| Xian-He-Cao (XHC; Agrimonia pilosa f. borealis (Kitag.) Chu) | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA |
| No      | 1.00     | NA     | NA      | 1.00       | NA     | NA      | 1.00     | NA     | NA     | 1.00       | NA     | NA      |
| Yes     | 0.65     | (0.58–0.73) | <0.001 | 0.65       | (0.58–0.73) | <0.001 | 1.19     | (0.64–2.19) | 0.580 | 0.90       | (0.48–1.68) | 0.739 |
| Dang-Gui (DG; Angelica sinensis (Okv.) Dier) | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA | 1.00 | NA | NA |
| No      | 1.00     | NA     | NA      | 1.00       | NA     | NA      | 1.00     | NA     | NA     | 1.00       | NA     | NA      |
| Yes     | 0.47     | (0.42–0.53) | <0.001 | 0.50       | (0.45–0.56) | <0.001 | 0.68     | (0.35–1.35) | 0.270 | 0.57       | (0.28–1.15) | 0.116 |

CHM, Chinese herbal medicine; HR, hazard ratio; aHR, adjusted hazard ratio; 95% CI, 95% confidence interval; NA, not applicable.

Patients with aplastic anemia (ICD9-CM code: 284).

Models adjusted for age, gender, comorbidities, and usages of immunosuppressive therapy, glucocorticoid usage, haematopoietic growth factor therapy, androgen therapy, chemotherapy, iron chelation therapy, and blood transfusion therapy.

Usages of therapies were applied within 1 year before or after the diagnosed date of aplastic anemia.

Significant p-values (p < 0.05) are highlighted in bold italic font.

Gui-Pi-Tang (GPT) was the herbal formula and was composed of 12 single herbs (Table 2).

Pin-yin and botanical plant names for Chinese herbs were obtained from the websites (http://www.americandragon.com/index.htm; http://old.tcmwiki.com; http://www.shen-nong. com/en/front/index.html; http://www.ipni.org; http://www.thefloraonline.org; http://www.worldfloraonline.org).

thereby reducing the secretion of interleukin-6 (IL-6) and TNF-α, which is known to inhibit erythropoiesis (Wang et al., 2017).

The third most commonly used CHM pairs were between GPT and XHC. Gui-Pi-Tang (GPT) contains 12 single herbs. We found that GPT was the most commonly used CHM herbal formula for AA patients. Similar studies also report that GPT is the most commonly prescribed CHM formula for treating anemia, acute myeloid leukemia, and osteopenia via hematopoiesis-stimulating activities (Kanai et al., 2005; Fleischer et al., 2017; Chen et al., 2018). It is also clinically prescribed to treat chronic immune thrombocytopenic purpura via autoantibodies suppression activities (Yamaguchi et al., 1993). XHC, also known as Agrimonia pilosa f. borealis (Kitag.) Chu, is a flowering plant of family Rosaceae. XHC exhibits anti-inflammatory, anti-oxidant and antimicrobial activities (Kim et al., 2017; Kim et al., 2020).

This study demonstrated that complementary CHM therapy may reduce overall and anemia-related mortalities among patients with AA. There are seven clinically used CHM products that are potentially useful for AA patients. However, the actual dose of specific CHMs in this prescription for patients was unknown, and the metabolism of the co-prescription pattern in humans, as well as potential confounders (i.e., body mass index, fatty tissue, lifestyles, personalized treatments, and social-economic status etc.) are not clarified in this study. Therefore, further randomized controlled trials and functional investigations of these potentially useful CHM products are necessary to validate their efficacy and safety in these patients.
DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because Only a limited number of databases allowed access to raw data from the Taiwanese NHIRD database. Requests to access the datasets should be directed to W-ML, wmliang@mail.cmu.edu.tw.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Review Board (IRB) issued the ethical approval to this study [CMUH107-REC3-074 (CR1)] at China Medical University Hospital. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

M-LC, Y-LH, W-ML, and Y-JL wrote the manuscript and interpreted the data. C-JC, T-ML, J-SC, F-JT, T-HL, C-CL, S-MH, and C-HC collected, assembled, and analyzed the data. F-JT, T-ML, W-ML, and Y-JL provided the study materials. W-ML and Y-JL designed, conceived the study, and amended the manuscript.

REFERENCES

Akram, Z., Ahmed, P., Kaijaya, S., Satti, T. M., Satti, H. S., Chaudhary, Q. U. N., et al. (2019). Epidemiological, Clinical and Genetic Characterization of Aplastic Anemia Patients in Pakistan. Ann. Hematol. 98, 301–312. doi:10.1007/s00277-018-3542-z

Bacigalupo, A., Brand, R., Oneto, R., Bruno, B., Socié, G., Passweg, J., et al. (2000). Treatment of Acquired Severe Aplastic Anemia: Bone Marrow Transplantation Compared with Immunosuppressive Therapy--The European Group for Blood and Marrow Transplantation Experience. Semin. Hematol. 37, 69–80. doi:10.1016/s0037-1963(00)90031-3

Chatterjee, R., and Law, S. (2018). Epigenetic and Microenvironmental Alterations in Bone Marrow Associated with ROS in Experimental Aplastic Anemia. Eur. J. Cell Biol. 97, 32–43. doi:10.1016/j.ejcb.2017.11.003

Chen, W. D., Huang, H. S., Su, Y. C., Chou, S. C., Ho, W. C., Kao, M. C., et al. (2018). The Characteristics and Prescription Patterns of Chinese Herbal Medicine in Clinical Practice for the Treatment of Aplasia. Taiwan J. Obstet. Gynecol. 57, 570–577. doi:10.1016/j.tjog.2018.06.030

Chen, Z., Cheng, L., Zhang, J., and Cui, X. (2020). Angelica Sinensis Polysaccharide Prevents Mitochondrial Apoptosis by Regulating the Treg/Th17 Ratio in Aplastic Anemia. J. Ethnopharmacol. 244, 329–333. doi:10.1016/j.jep.2020.112895

Cheng, C. F., Chien-Fu Lin, J., Tsai, F. J., Chen, C. J., Chiou, J. S., Chou, C. H., et al. (2019). Protective Effects and Network Analysis of Natural Compounds Obtained from Radix Dipsaci, Eucommiae Cortex, and Rhizoma Drynariae against RANKL-Induced Osteoclastogenesis. In Vitro. J. Ethnopharmacol 244, 112074. doi:10.1016/j.ejiph.2019.112074

Clucas, D. B., Fox, L. C., Wood, E. M., Hong, F. S., Gibson, J., Bajel, A., et al. (2019). Australian Aplastic Anaemia Registry Steering, C.Revisiting Acquired Aplastic Anaemia: Current Concepts in Diagnosis and Management. Intern. Med. J. 49, 152–159. doi:10.1111/imj.14140

Contejean, A., Resche-Rigon, M., Tamburini, J., Alcantara, M., Jardin, F., Lengliné, E., et al. (2019). Aplastic Anemia in the Elderly: a Nationwide Survey on Behalf of the French Reference Center for Aplastic Anemia. Haematologica 104, 256–262. doi:10.3324/haematol.2018.198440

Ding, S., Liu, C., Li, Y., Liu, H., Liu, Z., Chen, T., et al. (2019). Expression of C1q in the Serum of Patients with Non-severe A-plastic A-nemia, and its A-ssociation with D-isease S-everity. Mol. Med. Rep. 19, 1194–1202. doi:10.3892/ mmr.2018.9754

Fleischer, T., Chang, T. T., Chiang, J. H., Sun, M. F., and Yen, H. R. (2017). Improved Survival with Integration of Chinese Herbal Medicine Therapy in Patients with Acute Myeloid Leukemia: A Nationwide Population-Based Cohort Study. Integr. Cancer Ther. 16, 156–164. doi:10.1177/1534735416641171

Fu, R., Chen, T., Song, J., Wang, G., Li, L., Ruan, E., et al. (2017). De-escalation Empirical Antibiotic Therapy Improved Survival for Patients with Severe Aplastic Anemia Treated with Antithymocyte Globulin. Medicine (Baltimore) 96, e5905. doi:10.1097/MD.0000000000005905

Furlong, E., and Carter, T. (2020). Aplastic Anaemia: Current Concepts in Diagnosis and Management. J. Paediatr. Child. Health 56, 1023–1028. doi:10.1111/jpc.14996

Gale, R. P., Champlin, R. E., Feig, S. A., and Fitchen, J. H. (1981). Aplastic Anemia: Biology and Treatment. Ann. Intern. Med. 95, 477–494. doi:10.7326/0003-4819-95-4-477

Gao, R. L., and Chong, B. H. (2012). Research and Development of the Effective Components of Panaxdiol Saponin as New Chinese Patent Medicine for Treating Hemocytopenia. Chin. J. Integr. Med. 18, 897–902. doi:10.1007/s11655-012-1292-4

Gupta, S., Zhang, D., Yi, J., and Shao, J. (2004). Anticancer Activities of Oldenlandia Diffusa. J. Herb Pharmacother. 4, 21–33. doi:10.1080/157504601_03

Gurion, R., Gaffer-Givili, A., Paul, M., Vidal, L., Ben-Bassat, I., Yeshuron, M., et al. (2009). Hematopoietic Growth Factors in Aplastic Anemia Patients Treated with Immunosuppressive Therapy: Systematic Review and Meta-Analysis. Haematologica 94, 712–719. doi:10.3324/haematol.2008.020170

Ho, M. W., Li, T. M., Li, J. P., Chiou, J. S., Chiu, M. L., Chen, C. J., et al. (2021). Chinese Herbal Medicine Usage Reduces Overall Mortality in HIV-Infected Patients with Severe Aplastic Anemia. Eur. J. Intern. Med. 87, 377–383. doi:10.1016/j.ejim.2021.02.005

FUNDING

This study was supported by grants from the China Medical University, Taiwan (CMU109-MF-41, CMU109-MF-126, CMU109-S-18, CMU109-S-27, CMU110-MF-49, and CMU110-MF-115), the China Medical University Hospital, Taiwan (DMR-109-145, DMR-109-188, DMR-109–192, DMR-110–134, and DMR-110–152), and the Ministry of Science and Technology, Taiwan (MOST 107-2314-B-039-044-MY3, MOST 109-2320-B-039-035-MY3, and MOST 109-2410-H-039-002). The funding entities for this study had no role in the study design, data collection, data analysis, interpretation, or authorship of this manuscript.

ACKNOWLEDGMENTS

We are grateful to the Health Data Science Center at the China Medical University Hospital for providing administrative, technical, and funding support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.730776/full#supplementary-material
Patients with Osteoporosis or Fractures. *Front. Pharmacol.* 12, 593434. doi:10.3389/fphar.2021.593434

Huang, G. C., Chen, S. Y., Tsai, P. W., Ganzon, J. G., Lee, C. J., Shah, H. S., et al. (2016). Effects of Danshen on Hepatic Enzyme Induction and Subsequent Recovery. *Eur. J. Med. Chem.* 105, 171–178. doi:10.1016/j.ejmech.2015.12.012

Jiang, Z. Y., Yu, F. Q., Gao, R. L., Huang, Y. M., Zhu, Y., Chen, Y. H., et al. (2021). Treatment of Chronic Aplastic Anemia with Chinese Patent Medicine Pai-Neng-Da Capsule (SP23) for Replacing Androgen Partially: A Clinical Multi-Center Study. *Chin. J. Integr. Med.* 27, e051283-2. doi:10.1007/s11655-021-05128-3

Kim, G., Gan, R. Y., Zhang, D., Farha, A. K., Habimana, O., Mavumengwana, V., et al. (2019). Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia. *Int. J. Mol. Sci.* 20, 483. doi:10.3390/ijms20020483

Kanai, S., Taniguchi, N., and Higashino, H. (2005). Effect of Kami-Kihi-To (Ja-wei-gui-pi-tang) on Experimental Osteoporosis. *Am. J. Chin. Med.* 33, 41–48. doi:10.1006/jjcm.2004.1043

Kim, S. B., Hwang, S. H., Suh, H. W., and Lim, S. S. (2017). Phytochemical Analysis of the Traditional Chinese Herbal Medicine Ignatia and Its Anti-Tumor Activity of Oldenlandia Diffusa. *In Vitro. Zhongguo Zhong Xi Yi Jie He Za Zhi* 21, 370–374.

Shi, M., Huang, F., Deng, C., Wang, Y., and Kai, G. (2019). Bioactivities, Biosynthesis and Biotechnological Production of Phenolic Acids in Salvia Miltiorrhiza. *Crit. Rev. Food Sci. Nutr.* 59, 936–964. doi:10.1080/00097857.2018.1474170

Socio, G., Henry-Amir, M., Bacigalupo, A., Hows, J., Tichelli, A., Liu, J. P., et al. (1993). Malignant Tumors Occurring after Treatment of Aplastic Anemia. *European Bone Marrow Transplantation-Secondary Aplastic Anaemia Working Party. N. Engl. J. Med.* 329, 1152–1157. doi:10.1056/NEJM199310143291063

Speck, B., Gratwohl, A., Nissen, C., Leibundgut, U., Ruggero, D., Osterwalder, B., et al. (1984). Treatment of Severe Aplastic Anemia with Antilymphocyte Globulin or Bone-Marrow Transplantation. *Br. Med. J. (Clin. Res. Ed.)* 282, 860–863. doi:10.1136/bmj.282.6267.860

Sun, Z., Zhao, Y. N., Qian, S., Gao, R. L., Yin, L. M., Wang, L. P., et al. (2018). Ginseng-Derived Panaxadex Saponins Promote Hematopoiesis Recovery in Cyclophosphamide-Induced Myelosuppressive Mice: Potential Novel Treatment of Chemotherapy-Induced Cytopenias. *Chin. J. Integr. Med.* 24, 200–206. doi:10.1007/s11655-017-2754-8

Tsai, F. J., Cheng, C. F., Chen, C. J., Lin, C. Y., Wu, Y. F., Li, T. M., et al. (2019). Effects of Chinese Herbal Medicine Therapy on Survival and Hepatic Outcomes in Patients with Hepatitis C Virus Infection in Taiwan. *Phytomedicine* 57, 30–38. doi:10.1016/j.phymed.2018.09.237

Vahl, K., Göransson, M., Carlsson, K., Isakkson, C., Lenhoff, S., Sandstedt, A., et al. (2017). Incidence and Outcome of Acquired Aplastic Anemia: Real-World Data from Patients Diagnosed in Sweden from 2000-2011. *Haematologica* 102, 1683–1690. doi:10.3324/haematol.2017.169862

van der Hem, J. G. K., De Wrede, L. C., Brand, A., Veelken, H., Falkenburg, J. H. F., and Halks, C. J. M. (2017). Long-term Risk of Cancer Development in Adult Patients with Idiopathic Aplastic Anemia after Treatment with Anti-thymocyte Globulin. *Haematologica* 102, e382–e383. doi:10.3324/haematol.2017.171215

Wang, M. S., Li, J., Di, H. X., Li, Z. L., Yang, S. L., Hou, W., et al. (2007). Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia. *J. Ethnopharmacol.* 111, 39. doi:10.1016/j.jep.2007.06.031

Wu, Y., Wei, H. P., and Wang, J. B. (2009). Anti-complement Activity of Polysaccharide B3-PS2 Purified from Patients Treated with Anti-thymocyte Globulin. *Am. J. Chin. Med.* 37, 43–70. doi:10.1142/9789812798842_0004

Wu, Y., and Chen, D. F. (2008). Anti-Complementary Effect of Polysaccharide B3-PS2 Purified from Herba Scutellariae Barbatae. *Immunopharmacol. Immunotoxicol.* 30, 697–701. doi:10.1080/01634468809639031

Wu, Y., Wei, H. P., and Wang, J. B. (2009). Anti-complement Activity of Polysaccharide B3-PS2 Purified from Herba Scutellariae Barbatae. *Yao Xue Xue Bao* 44, 615–619. doi:10.1080/01680312003095314

Wu, Y., Li, T. M., Chen, S. I., Chen, C. J., Chou, J. S., Lin, M. K., et al. (2020). Complementary Chinese Herbal Medicine Therapy Improves Survival in Patients with Pompholyx. *Front. Pharmacol.* 11, 594886. doi:10.3389/fphar.2020.594886

Yamaguchi, K., Kido, H., Kawakatsu, T., Fukuroi, T., Suzuki, M., Yanabu, M., et al. (2013). Impact of Chinese Herbal Medicine Therapy on Survival and Hematological Parameters in Severe Aplastic Anemia. *Front. Oncol.* 3, 70. doi:10.3389/fo.oncol.2013.00070

Zhou, H. M., Wang, J. H., Li, J. H., Yang, X. T., and Yuan, H. C. (2017). Anti-complement Activity of the Traditional Chinese Medicinal Herbs Oldenlandia Diffusa and O. Corymbosa and a New Valuation of Their Biological Potential. *Biotechnological Production of Phenolic Acids in Salvia Miltiorrhiza.*

Zhou, H. M., Wang, J. H., Li, J. H., Yang, X. T., and Yuan, H. C. (2017). Anti-complement Activity of the Traditional Chinese Medicinal Herbs Oldenlandia Diffusa and O. Corymbosa and a New Valuation of Their Biological Potential. *Biotechnological Production of Phenolic Acids in Salvia Miltiorrhiza.*

Zhou, H. M., Wang, J. H., Li, J. H., Yang, X. T., and Yuan, H. C. (2017). Anti-complement Activity of the Traditional Chinese Medicinal Herbs Oldenlandia Diffusa and O. Corymbosa and a New Valuation of Their Biological Potential. *Biotechnological Production of Phenolic Acids in Salvia Miltiorrhiza.*
Zhu, X., and Zhu, B. (2001). Effect of Astragalus Membranaceus Injection on Megakaryocyte Hematopoiesis in Anemic Mice. *Hua Xi Yi Ke Da Xue Xue Bao* 32, 590–592.

Zhu, C., Gao, Y., Jiang, T., Hao, C., Gao, Z., and Sun, Y. (2015). Meta-analysis of Huangqi Injection for the Adjunctive Therapy of Aplastic Anemia. *Int. J. Clin. Exp. Med.* 8, 10256–10264.

Zhu, H., Luo, R. M., Luan, Z., Lee, V., Zhu, Y. P., Luo, C. J., et al. (2016). Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation for Children with Severe Aplastic Anaemia. *Br. J. Haematol.* 174, 799–805. doi:10.1111/bjh.14110

Zhu, H., Liang, Q. H., Xiong, X. G., Wang, Y., Zhang, Z. H., Sun, M. J., et al. (2018a). Anti-Inflammatory Effects of P-Coumaric Acid, a Natural Compound of Oldenlandia Diffusa, on Arthritis Model Rats. *Evid. Based Complement. Alternat Med.* 2018, 5198594. doi:10.1155/2018/5198594

Zhu, N., Wu, D., and Ye, B. (2018b). The Progress of Traditional Chinese Medicine in the Treatment of Aplastic Anemia. *J. Transl Int. Med.* 6, 159–164. doi:10.2478/jtim-2018-0031

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Chiu, Hsu, Chen, Li, Chiou, Tsai, Lin, Liao, Huang, Chou, Liang and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.